

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED 大健康國際集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2211)

PROPOSED INTRODUCTION OF STRATEGIC INVESTOR BY THE CONTROLLING SHAREHOLDER

This announcement is made pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on the Main Board (the “**Listing Rules**”) of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors (the “**Directors**”) of Universal Health International Group Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) was informed by Mr. Jin Dongtao (“**Mr. Jin**”), the controlling shareholder (as defined in the Listing Rules) and the chairman of the Company, on 25 January 2016 that he intends, through his wholly-owned company, namely Asia Health Century International Inc. (“**Asia Health**”), to dispose not more than 20% interest in the issued share capital of the Company (the “**Disposal**”) to Zhongrong International Trust Company Limited (“**Zhongrong Trust**”) so as to introduce strategic investor to the Company. Further update of the Disposal will be announced by the Company as and when appropriate. Zhongrong Trust is a third party independent of and not connected with the Company and its connected persons (as defined in the Listing Rules). Upon completion of the Disposal, Zhongrong Trust will become the 2nd largest shareholder of the Company and both Mr. Jin and Asia Health will remain as the controlling shareholders of the Company.

INFORMATION ON ZHONGRONG TRUST

Zhongrong Trust was established in 1987. Zhongrong Trust is a financial institute authorized by the China Banking Regulatory Commission (CBRC). After over 20 years of development, Zhongrong Trust has become a major financial enterprise with sound corporate governance and effective risk

control. Zhongrong Trust is proactively engaged in business of innovation and has its business presence across China. Zhongrong Trust has established a sound and effective management mechanism and an integrated business management information system and has built a professional team with sophisticated investment concept and rich experiences, especially a core business team with dealing experience in securities, futures and other financial instruments in the domestic and international financial market and also extensive experiences in marketable securities, financial derivatives, venture capital and other fields.

INFORMATION ON THE GROUP

As the Group is engaged in universal health industry business and leveraging on its professional sectors, the Group embraced the trend of “Universal health + Internet”. Our core teams include entity operation, internet platform, cross-border e-commerce operation and capital operation. The Group owns 949 store outlets across the country and 4 flagship stores in Hong Kong. Meanwhile, the Group has established in-depth cooperation relationship with many business organizations from Russia, South Korea, Japan, New Zealand, Australia, the U.S.A and other countries in the world. Furthermore, the Group is a major private pharmaceutical retail chain enterprise and pharmaceutical distributor in the PRC, with over 6,500 distributor clients across the country.

Seizing the development opportunities of the era and benefiting from its advantage as a listed company in Hong Kong, the Group has, since March 2015, proactively developed the “Universal health + Internet” business by implementing the strategy of “diversified product lines, cross-border development and integrated O2O platforms”, so as to expand its core business into the field of universal health. With the concept of “Healthy China” becoming the national strategy and embracing the “Universal health + Internet” development strategy, Universal Health International adheres to the cross-border marketing concept of “introducing products to and from the global market” by establishing an international universal health branding and marketing platform combining cross-border ecommerce, international trade, social network, O2O platform, training for operation and capital operation.

While maintaining its original core businesses such as branded product retail and selling and distributing pharmaceutical products, the Group continued to actively explore the international trading business by expanding into imported and domestic healthcare products, health food and other non-pharmaceutical products, as well as traditional nutrition supplements (including cubilose, ginseng, cordyceps etc.), healthcare devices, cosmeceutical and other products, so as to promote development of its universal health business.

Mr. Jin and Zhongrong Trust are working closely to facilitate this strategic cooperation. However, there is no assurance that the Disposal will materialize or eventually be consummated, shareholders and potential investors of the Company are urged to exercise extreme caution when dealing in the Shares and/or other securities of the Company.

The Company considers that the introduction of Zhongrong Trust will facilitate the Company to implement its strategy of “Universal health +” business, enhance its corporate governance, upgrade its business, develop its China and international markets, implement relevant mechanism for combination between industry and finance, improve its competitiveness and improve its reputation in the industry.

By order of the Board
Universal Health International Group Holding Limited
Chu Chuanfu
Executive Director

Hong Kong, 25 January 2016

As at the date of this announcement, the board of directors of the Company comprises four executive directors, namely, Mr. Jin Dongtao, Mr. Jin Dongkun, Mr. Chu Chuanfu and Mr. Zhao Zehua and three independent non-executive directors, namely, Mr. Cheng Sheung Hing, Ms. Chiang Su Hui Susie and Ms. Hao Jia.